title: (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
abstract: We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
authors.affiliation: Department of Hematology, Odense University Hospital , Denmark.
authors.forename: Karen Juul
authors.initials: KJ
authors.lastname: Mylam
authors.forename: Lale
authors.initials: L
authors.lastname: Kostakoglu
authors.forename: Martin
authors.initials: M
authors.lastname: Hutchings
authors.forename: Morton
authors.initials: M
authors.lastname: Coleman
authors.forename: Dominick
authors.initials: D
authors.lastname: Lamonica
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Louis F
authors.initials: LF
authors.lastname: Diehl
authors.forename: Anne L
authors.initials: AL
authors.lastname: Nielsen
authors.forename: Paw
authors.initials: P
authors.lastname: Jensen
authors.forename: Annika
authors.initials: A
authors.lastname: Loft
authors.forename: Helle W
authors.initials: HW
authors.lastname: Hendel
authors.forename: Victor
authors.initials: V
authors.lastname: Iyer
authors.forename: Sirpa
authors.initials: S
authors.lastname: Leppä
authors.forename: Sirkku
authors.initials: S
authors.lastname: Jyrkkiö
authors.forename: Harald
authors.initials: H
authors.lastname: Holte
authors.forename: Mikael
authors.initials: M
authors.lastname: Eriksson
authors.forename: Dorte
authors.initials: D
authors.lastname: Gillstrøm
authors.forename: Per B
authors.initials: PB
authors.lastname: Hansen
authors.forename: Marko
authors.initials: M
authors.lastname: Seppänen
authors.forename: Karin
authors.initials: K
authors.lastname: Hjorthaug
authors.forename: Peter de Nully
authors.initials: Pde N
authors.lastname: Brown
authors.forename: Lars M
authors.initials: LM
authors.lastname: Pedersen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003718:Denmark; D005260:Female; D005387:Finland; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D009664:Norway; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D015996:Survival Rate; D013548:Sweden; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014481:United States; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Deauville 5-point scale; Interim PET/CT; diffuse large B-cell lymphoma; predictive value